Works by Souhami, Elisabeth

Results: 34

The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 9, p. 3791, doi. 10.1111/dom.15724

By:

Liu, Ming;
Gu, Weijun;
Chen, Li;
Li, Yanbing;
Kuang, Hongyu;
Du, Jianling;
Alvarez, Agustina;
Lauand, Felipe;
Souhami, Elisabeth;
Zhang, Jiewen;
Xu, Weiya;
Du, Qin;
Mu, Yiming

Publication type:

Article

iGlarLixi provides a higher derived time‐in‐range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis.

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 2005, doi. 10.1111/dom.15074

By:

Guo, Xiaohui;
Yang, Wenying;
Zhang, Junqing;
Dong, Xiaolin;
Liu, Ming;
Gu, Shenghong;
Lauand, Felipe;
Li, Lingyu;
Huang, Qiong;
Kang, Lei;
Souhami, Elisabeth

Publication type:

Article

Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial.

Published in:

Diabetes, Obesity & Metabolism, 2022, v. 24, n. 12, p. 2391, doi. 10.1111/dom.14825

By:

McCrimmon, Rory J.;
Home, Philip;
Cheng, Alice;
Giorgino, Francesco;
Fonseca, Vivian;
Souhami, Elisabeth;
Alvarez, Agustina;
Picard, Pascaline;
Rosenstock, Julio

Publication type:

Article

Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan‐L‐CN randomized controlled trial

Published in:

Diabetes, Obesity & Metabolism, 2022, v. 24, n. 11, p. 2182, doi. 10.1111/dom.14803

By:

Yuan, Xiaoyong;
Guo, Xiaohui;
Zhang, Junqing;
Dong, Xiaolin;
Lu, Yibing;
Pang, Wuyan;
Gu, Shenghong;
Niemoeller, Elisabeth;
Ping, Lin;
Nian, Gaowei;
Souhami, Elisabeth

Publication type:

Article

Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan‐O‐AP randomized controlled trial.

Published in:

Diabetes, Obesity & Metabolism, 2022, v. 24, n. 8, p. 1522, doi. 10.1111/dom.14722

By:

Yang, Wenying;
Dong, Xiaolin;
Li, Qingju;
Cheng, Zhifeng;
Yuan, Guoyue;
Liu, Ming;
Xiao, Jianzhong;
Gu, Shenghong;
Niemoeller, Elisabeth;
Chen, Lijuan;
Ping, Lin;
Souhami, Elisabeth

Publication type:

Article

Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan‐O randomized trial.

Published in:

Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 34, doi. 10.1111/dom.14543

By:

Davies, Melanie J.;
Rosenstock, Julio;
Ali, Amar;
Russell‐Jones, David;
Souhami, Elisabeth;
Palmer, Karen;
Ji, Chen;
Niemoeller, Elisabeth;
Skolnik, Neil

Publication type:

Article

Switching to iGlarLixi versus continuation of a daily or weekly glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) in insufficiently controlled type 2 diabetes: A LixiLan‐G trial subgroup analysis by HbA1c and GLP‐1 RA use at screening

Published in:

Diabetes, Obesity & Metabolism, 2021, v. 23, n. 6, p. 1331, doi. 10.1111/dom.14345

By:

Rosenstock, Julio;
Blonde, Lawrence;
Aroda, Vanita R.;
Frias, Juan;
Souhami, Elisabeth;
Ji, Chen;
Niemoeller, Elisabeth;
Del Prato, Stefano

Publication type:

Article

Impact of disease duration and β‐cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon‐like peptide‐1 receptor agonist therapy: Exploratory analyses from the LixiLan‐G trial.

Published in:

Diabetes, Obesity & Metabolism, 2020, v. 22, n. 9, p. 1567, doi. 10.1111/dom.14068

By:

Del Prato, Stefano;
Frias, Juan Pablo;
Blonde, Lawrence;
Aroda, Vanita R.;
Shehadeh, Niam;
Saremi, Aramesh;
Dex, Terry;
Niemoeller, Elisabeth;
Souhami, Elisabeth;
Liu, Minzhi;
Rosenstock, Julio

Publication type:

Article

Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide ( iGlarLixi) vs insulin glargine and lixisenatide monocomponents

Published in:

Diabetes, Obesity & Metabolism, 2017, v. 19, n. 12, p. 1798, doi. 10.1111/dom.12980

By:

Davies, Melanie J.;
Leiter, Lawrence A.;
Guerci, Bruno;
Grunberger, George;
Ampudia‐Blasco, F. Javier;
Yu, Christine;
Stager, William;
Niemoeller, Elisabeth;
Souhami, Elisabeth;
Rosenstock, Julio

Publication type:

Article

Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial

Published in:

Diabetes, Obesity & Metabolism, 2017, v. 19, n. 10, p. 1408, doi. 10.1111/dom.12961

By:

Wysham, Carol;
Bonadonna, Riccardo C.;
Aroda, Vanita R.;
Puig Domingo, Manuel;
Kapitza, Christoph;
Stager, William;
Yu, Christine;
Niemoeller, Elisabeth;
Souhami, Elisabeth;
Bergenstal, Richard M.

Publication type:

Article

Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study.

Published in:

2021

By:

Blonde, Lawrence;
Rosenstock, Julio;
Frias, Juan;
Birkenfeld, Andreas L.;
Niemoeller, Elisabeth;
Souhami, Elisabeth;
Ji, Chen;
Del Prato, Stefano;
Aroda, Vanita R.

Publication type:

journal article

Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.

Published in:

2019

By:

Blonde, Lawrence;
Rosenstock, Julio;
Del Prato, Stefano;
Henry, Robert;
Shehadeh, Naim;
Frias, Juan;
Niemoeller, Elisabeth;
Souhami, Elisabeth;
Chen Ji;
Aroda, Vanita R.;
Ji, Chen

Publication type:

journal article

Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39:1972–1980

Published in:

2017

By:

Aroda, Vanita R;
Rosenstock, Julio;
Wysham, Carol;
Unger, Jeffrey;
Bellido, Diego;
González-Gálvez, Guillermo;
Takami, Akane;
Guo, Hailing;
Niemoeller, Elisabeth;
Souhami, Elisabeth;
Bergenstal, Richard M;
LixiLan-L Trial Investigators

Publication type:

journal article

Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026-2035.

Published in:

2017

By:

Rosenstock, Julio;
Aronson, Ronnie;
Grunberger, George;
Hanefeld, Markolf;
Piatti, PierMarco;
Serusclat, Pierre;
Cheng, Xi;
Zhou, Tianyue;
Niemoeller, Elisabeth;
Souhami, Elisabeth;
Davies, Melanie;
LixiLan-O Trial Investigators

Publication type:

journal article

Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.

Published in:

2016

By:

Aroda, Vanita R.;
Rosenstock, Julio;
Wysham, Carol;
Unger, Jeffrey;
Bellido, Diego;
Gonzáalez-Gálvez, Guillermo;
Takami, Akane;
Hailing Guo;
Niemoeller, Elisabeth;
Souhami, Elisabeth;
Bergenstal, Richard M.;
González-Gálvez, Guillermo;
Guo, Hailing;
LixiLan-L Trial Investigators

Publication type:

journal article

Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.

Published in:

2016

By:

Rosenstock, Julio;
Aronson, Ronnie;
Grunberger, George;
Hanefeld, Markolf;
Piatti, PierMarco;
Serusclat, Pierre;
Xi Cheng;
Tianyue Zhou;
Niemoeller, Elisabeth;
Souhami, Elisabeth;
Davies, Melanie;
Cheng, Xi;
Zhou, Tianyue;
LixiLan-O Trial Investigators

Publication type:

journal article

Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial.

Published in:

2016

By:

Rosenstock, Julio;
Diamant, Michaela;
Aroda, Vanita R.;
Silvestre, Louise;
Souhami, Elisabeth;
Tianyue Zhou;
Perfetti, Riccardo;
Fonseca, Vivian;
Zhou, Tianyue;
LixiLan PoC Study Group

Publication type:

journal article

Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial.

Published in:

2016

By:

Rosenstock, Julio;
Guerci, Bruno;
Hanefeld, Markolf;
Gentile, Sandro;
Aronson, Ronnie;
Tinahones, Francisco J.;
Roy-Duval, Christine;
Souhami, Elisabeth;
Wardecki, Marek;
Ye, Jenny;
Perfetti, Riccardo;
Heller, Simon;
GetGoal Duo-2 Trial Investigators

Publication type:

journal article

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).

Published in:

2013

By:

Riddle, Matthew C;
Forst, Thomas;
Aronson, Ronnie;
Sauque-Reyna, Leobardo;
Souhami, Elisabeth;
Silvestre, Louise;
Ping, Lin;
Rosenstock, Julio

Publication type:

journal article

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine.

Published in:

Diabetes Care, 2013, v. 36, n. 9, p. 2497, doi. 10.2337/dc12-2462

By:

RIDDLE, MATTHEW C.;
FORST, THOMAS;
ARONSON, RONNIE;
SAUQUE-REYNA, LEOBARDO;
SOUHAMI, ELISABETH;
SILVESTRE, LOUISE;
LIN PING;
ROSENSTOCK, JULIO

Publication type:

Article

Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results.

Published in:

Diabetes Therapy, 2022, v. 13, n. 1, p. 205, doi. 10.1007/s13300-021-01180-1

By:

Guja, Cristian;
Giorgino, Francesco;
Blonde, Lawrence;
Ali, Amar;
Prázný, Martin;
Meier, Juris J.;
Souhami, Elisabeth;
Lubwama, Robert;
Ji, Chen;
Rosenstock, Julio

Publication type:

Article

Cost-Effectiveness of iGlarLixi Versus iDegLira in Type 2 Diabetes Mellitus Inadequately Controlled by GLP-1 Receptor Agonists and Oral Antihyperglycemic Therapy.

Published in:

Diabetes Therapy, 2021, v. 12, n. 12, p. 3231, doi. 10.1007/s13300-021-01156-1

By:

McCrimmon, Rory J.;
Lamotte, Mark;
Ramos, Mafalda;
Alsaleh, Abdul Jabbar Omar;
Souhami, Elisabeth;
Lew, Elisheva

Publication type:

Article

iGlarLixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L.

Published in:

Diabetes Therapy, 2018, v. 9, n. 1, p. 373, doi. 10.1007/s13300-017-0336-6

By:

Niemoeller, Elisabeth;
Souhami, Elisabeth;
Wu, Yujun;
Jensen, Klaus H.

Publication type:

Article

Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes.

Published in:

2019

By:

Schmider, Wolfgang;
Niemoeller, Elisabeth;
Belder, Rene;
Lee, Michelle;
Souhami, Elisabeth;
Frias, Juan P.

Publication type:

journal article

Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day: An analysis using continuous glucose monitoring.

Published in:

2017

By:

Bergenstal, Richard M.;
Strock, Ellie;
Mazze, Roger;
Powers, Margaret A.;
Monk, Arlene M.;
Richter, Sara;
Souhami, Elisabeth;
Ahrén, Bo

Publication type:

journal article

1-LB: Advancing Therapy in Basal Insulin Users with Type 2 Diabetes (T2D): Hypoglycemia as a Function of HbA1c in the SoliMix Trial.

Published in:

Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-1-LB

By:

MCCRIMMON, RORY J.;
HOME, PHILIP;
CHENG, ALICE Y.;
GIORGINO, FRANCESCO;
FONSECA, VIVIAN;
SOUHAMI, ELISABETH;
ALVAREZ, AGUSTINA;
BOSS, ANDERS H.;
MELAS-MELT, LYDIE;
ROSENSTOCK, JULIO

Publication type:

Article

749-P: Advancing Therapy in Uncontrolled Basal Insulin (BI)-Treated Type 2 Diabetes (T2D): Subanalysis of the SoliMix Trial Outside Europe.

Published in:

Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-749-P

By:

FONSECA, VIVIAN;
ROSENSTOCK, JULIO;
CHENG, ALICE Y.;
EMRAL, RIFAT;
SAUQUE-REYNA, LEOBARDO;
MOHAN, VISWANATHAN;
AL SIFRI, SAUD N.;
ALVAREZ, AGUSTINA;
DJABALLAH, KHIER;
PICARD, PASCALINE;
SOUHAMI, ELISABETH;
MCCRIMMON, RORY J.

Publication type:

Article

748-P: Advancing Therapy in Uncontrolled Basal Insulin (BI)-Treated Type 2 Diabetes (T2D): Subanalysis of the SoliMix Trial in Participants in Europe.

Published in:

Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-748-P

By:

CHENG, ALICE Y.;
MCCRIMMON, RORY J.;
FONSECA, VIVIAN;
TRESCOLI, CARLOS;
HALUZIK, MARTIN;
SEUFERT, JOCHEN;
ALVAREZ, AGUSTINA;
SOUHAMI, ELISABETH;
PICARD, PASCALINE;
BONNEMAIRE, MIREILLE;
ROSENSTOCK, JULIO

Publication type:

Article

746-P: Advancing Therapy in Uncontrolled Basal Insulin-Treated Type 2 Diabetes (T2D): Nocturnal Hypoglycemia in the SoliMix Trial.

Published in:

Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-746-P

By:

MCCRIMMON, RORY J.;
CHENG, ALICE Y.;
FONSECA, VIVIAN;
CHOZA, RICARDO;
ALESSA, THAMER;
ALVAREZ, AGUSTINA;
SOUHAMI, ELISABETH;
BOSS, ANDERS H.;
PICARD, PASCALINE;
ROSENSTOCK, JULIO

Publication type:

Article

88-LB: Similar Efficacy and Safety of IGlarLixi When Initiated in Patients with Type 2 Diabetes (T2D) with or without Concomitant Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) Use in a Randomized Controlled Trial (RCT) and Real-World Setting.

Published in:

Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-88-LB

By:

ROSENSTOCK, JULIO;
ALI, AMAR;
MEIER, JURIS J.;
GIORGINO, FRANCESCO;
GUJA, CRISTIAN;
PRAZNY, MARTIN;
LUBWAMA, ROBERT;
SOUHAMI, ELISABETH;
BLONDE, LAWRENCE

Publication type:

Article

149-OR: LixiLan-G: A Randomized Trial Assessing Switching to iGlarLixi vs. Continuation of Daily or Weekly GLP-1RA in T2D Inadequately Controlled by a GLP-1RA and OAD(s).

Published in:

Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-149-OR

By:

BLONDE, LAWRENCE;
ROSENSTOCK, JULIO;
PRATO, STEFANO DEL;
HENRY, ROBERT R.;
SHEHADEH, NAIM;
NIEMOELLER, ELISABETH;
SOUHAMI, ELISABETH;
WU, JUNLONG;
WANG, XIANGLING;
JI, CHEN;
ARODA, VANITA R.

Publication type:

Article

1146-P: Switching to iGlarLixi vs. Continued Treatment of GLP-1RA: Comparative Analysis by Daily or Weekly GLP-1RAs in the LixiLan-G Trial.

Published in:

Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1146-P

By:

ROSENSTOCK, JULIO;
BLONDE, LAWRENCE;
PRATO, STEFANO DEL;
HENRY, ROBERT R.;
SHEHADEH, NAIM;
NIEMOELLER, ELISABETH;
SOUHAMI, ELISABETH;
WU, JUNLONG;
WANG, XIANGLING;
JI, CHEN;
ARODA, VANITA R.

Publication type:

Article

1139-P: Influence of Screening HbA<sub>1c</sub> Levels on Glucose Control Achieved when Switching to iGlarLixi in T2D Inadequately Controlled on GLP-1RA and OAD(s).

Published in:

Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1139-P

By:

PRATO, STEFANO DEL;
BLONDE, LAWRENCE;
HENRY, ROBERT R.;
ARODA, VANITA R.;
SHEHADEH, NAIM;
NIEMOELLER, ELISABETH;
SOUHAMI, ELISABETH;
WU, JUNLONG;
WANG, XIANGLING;
JI, CHEN;
ROSENSTOCK, JULIO

Publication type:

Article

1134-P: Efficacy of iGlarLixi in Adults with Type 2 Diabetes Inadequately Controlled on Two or More Oral Antidiabetic Agents.

Published in:

Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1134-P

By:

SKOLNIK, NEIL;
NIEMOELLER, ELISABETH;
SOUHAMI, ELISABETH;
MENEGHINI, LUIGI

Publication type:

Article